KalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by Analysts at TD Cowen

Analysts at TD Cowen assumed coverage on shares of KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) in a report issued on Tuesday, MarketBeat reports. The brokerage set a "buy" rating and a $30.00 price target on the specialty pharmaceutical company's stock. TD Cowen's target price indicates a potential upside of 242.47% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $25.00.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded up $0.08 on Tuesday, hitting $8.76. 194,774 shares of the company were exchanged, compared to its average volume of 200,719. The company's 50 day moving average price is $9.56 and its two-hundred day moving average price is $11.37. The firm has a market capitalization of $432.90 million, a price-to-earnings ratio of -2.41 and a beta of 0.86. KalVista Pharmaceuticals has a one year low of $7.97 and a one year high of $16.88.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares of the company's stock, valued at $2,677,311. This represents a 2.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares of the company's stock, valued at approximately $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock worth $304,086 in the last three months. Insiders own 10.50% of the company's stock.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KALV. Bank of New York Mellon Corp increased its stake in shares of KalVista Pharmaceuticals by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company's stock valued at $1,597,000 after buying an additional 23,547 shares during the period. Rhumbline Advisers boosted its stake in shares of KalVista Pharmaceuticals by 12.5% in the 2nd quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company's stock valued at $627,000 after purchasing an additional 5,908 shares during the last quarter. ClariVest Asset Management LLC grew its position in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company's stock worth $673,000 after buying an additional 1,535 shares during the period. Nicholas Investment Partners LP lifted its holdings in KalVista Pharmaceuticals by 0.9% in the second quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company's stock valued at $2,172,000 after buying an additional 1,714 shares during the period. Finally, Evoke Wealth LLC bought a new position in KalVista Pharmaceuticals in the second quarter valued at approximately $181,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).